ALT
Price
$6.20
Change
-$0.19 (-2.97%)
Updated
Sep 6 closing price
59 days until earnings call
DBVT
Price
$0.80
Change
-$0.01 (-1.23%)
Updated
Sep 6 closing price
Ad is loading...

ALT vs DBVT

Header iconALT vs DBVT Comparison
Open Charts ALT vs DBVTBanner chart's image
Altimmune
Price$6.20
Change-$0.19 (-2.97%)
Volume$1.64M
CapitalizationN/A
DBV Technologies SA
Price$0.80
Change-$0.01 (-1.23%)
Volume$45.18K
CapitalizationN/A
View a ticker or compare two or three
ALT vs DBVT Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DBVT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ALT vs. DBVT commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a StrongSell and DBVT is a Hold.

COMPARISON
Comparison
Sep 08, 2024
Stock price -- (ALT: $6.39 vs. DBVT: $0.81)
Brand notoriety: ALT and DBVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 49% vs. DBVT: 28%
Market capitalization -- ALT: $440.64M vs. DBVT: $86.7M
ALT [@Biotechnology] is valued at $440.64M. DBVT’s [@Biotechnology] market capitalization is $86.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $584.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileDBVT’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • DBVT’s FA Score: 0 green, 5 red.
According to our system of comparison, both ALT and DBVT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 2 TA indicator(s) are bullish while DBVT’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 2 bullish, 8 bearish.
  • DBVT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DBVT is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а -3.25% price change this week, while DBVT (@Biotechnology) price change was -9.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.71%. For the same industry, the average monthly price growth was +3.67%, and the average quarterly price growth was -3.87%.

Reported Earning Dates

ALT is expected to report earnings on Nov 05, 2024.

DBVT is expected to report earnings on Jul 29, 2024.

Industries' Descriptions

@Biotechnology (-2.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($441M) has a higher market cap than DBVT($86.7M). ALT YTD gains are higher at: -43.156 vs. DBVT (-57.704). DBVT has higher annual earnings (EBITDA): -83.62M vs. ALT (-100.91M). ALT has more cash in the bank: 165M vs. DBVT (66.2M). ALT has less debt than DBVT: ALT (1.86M) vs DBVT (7.59M). ALT has higher revenues than DBVT: ALT (409K) vs DBVT (0).
ALTDBVTALT / DBVT
Capitalization441M86.7M509%
EBITDA-100.91M-83.62M121%
Gain YTD-43.156-57.70475%
P/E RatioN/AN/A-
Revenue409K0-
Total Cash165M66.2M249%
Total Debt1.86M7.59M25%
FUNDAMENTALS RATINGS
ALT vs DBVT: Fundamental Ratings
ALT
DBVT
OUTLOOK RATING
1..100
6550
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
81100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4090
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DBVT's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for ALT (83) in the Miscellaneous Commercial Services industry. This means that DBVT’s stock grew somewhat faster than ALT’s over the last 12 months.

ALT's Profit vs Risk Rating (81) in the Miscellaneous Commercial Services industry is in the same range as DBVT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to DBVT’s over the last 12 months.

ALT's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as DBVT (98) in the Biotechnology industry. This means that ALT’s stock grew similarly to DBVT’s over the last 12 months.

ALT's Price Growth Rating (40) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for DBVT (90) in the Biotechnology industry. This means that ALT’s stock grew somewhat faster than DBVT’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as DBVT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to DBVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTDBVT
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 9 days ago
85%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DBVT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BPEMX9.14N/A
N/A
Boston Partners Emerging Markets Instl
MKCPX26.79N/A
N/A
BlackRock Sustainable Balanced K
FAAIX28.12-0.02
-0.07%
Fidelity Advisor Asset Manager 70% I
DHTAX25.11-0.19
-0.75%
Diamond Hill Select Inv
RLCAX9.13-0.09
-0.98%
Columbia Disciplined Value A

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
-1.62%
PLRX - ALT
42%
Loosely correlated
+4.13%
EDIT - ALT
42%
Loosely correlated
-0.43%
VKTX - ALT
42%
Loosely correlated
-4.66%
INZY - ALT
41%
Loosely correlated
-0.19%
CLDX - ALT
41%
Loosely correlated
-2.38%
More

DBVT and

Correlation & Price change

A.I.dvisor tells us that DBVT and CRDF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DBVT and CRDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DBVT
1D Price
Change %
DBVT100%
-1.83%
CRDF - DBVT
32%
Poorly correlated
+0.91%
SNPX - DBVT
29%
Poorly correlated
-0.84%
GLSI - DBVT
29%
Poorly correlated
-0.45%
ALT - DBVT
26%
Poorly correlated
-1.62%
RXRX - DBVT
25%
Poorly correlated
+1.15%
More